Stock listing
4588 Stock Price, News, Filings & Events — Oncolys Biopharma, Inc.
Selected listing: 4588 · TSE · JPY · JP
This page tracks Oncolys Biopharma, Inc.'s 4588:TSE listing on TSE in JPY for JP, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 4588:TSE. 4588:TSE is the stock-level entry point for investors researching Oncolys Biopharma, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Oncolys Biopharma, Inc. is a public company listed under the ticker 4588 in the Japanese market. The company has a market capitalization of approximately 455.27 million USD. Oncolys focuses on developing innovative biopharmaceuticals to address unmet medical needs.

- Ticker
- 4588:TSE
- Asset type
- Stock
- Market cap
- $1.10B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- TSE
- Currency
- JPY
Oncolys Biopharma, Inc. 4588:TSE stock context
This page tracks Oncolys Biopharma, Inc.'s 4588:TSE listing on TSE in JPY for JP, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 4588:TSE. 4588:TSE is the stock-level entry point for investors researching Oncolys Biopharma, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Oncolys Biopharma, Inc. is a public company listed under the ticker 4588 in the Japanese market. The company has a market capitalization of approximately 455.27 million USD. Oncolys focuses on developing innovative biopharmaceuticals to address unmet medical needs.
Latest news from Oncolys Biopharma, Inc.
Non-consolidated Financial Results for the Six Months Ended June 30, 2026 [Japanese GAAP]
August 7, 2026
Oncolys BioPharma Announces Full Marketing Approval in Japan for Telomelysin for the Treatment of Esophageal Cancer
June 8, 2026
Oncolys BioPharma : Non-consolidated Financial Results for the Three Months Ended March 31, 2026
May 8, 2026
Oncolys BioPharma : Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2025
February 8, 2026
Oncolys BioPharma : Non-consolidated Financial Results for the Nine Months Ended September 30, 2025
November 7, 2025
Research Oncolys Biopharma, Inc.
Oncolys Biopharma, Inc. investor report
Review AI stock analysis and investor report context for 4588:TSE.
Oncolys Biopharma, Inc. company profile
View the public company page for Oncolys Biopharma, Inc. on 6ix.
Oncolys Biopharma, Inc. news
Read company news and market updates connected to Oncolys Biopharma, Inc..
Oncolys Biopharma, Inc. investor events
Find investor webinars, events, and replay context for Oncolys Biopharma, Inc..